Crescent Biopharma, Inc.

CBIO Nasdaq SEC CIK 1253689
Follow Crescent Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $3.1M
Net income −$37.7M −53.3% vs same quarter last year
EPS, diluted -
Operating cash flow −$26.9M −53.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$10.8M
$1M
$0
$3.1M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$10.8M$153.9K
FY24-$37.9K
FY23$10K$36.9K
FY22$75K−$46.7M
FY21$1.2M−$63.4M
FY20$10.2M−$51M
FY19-−$57.9M
FY18-−$48.3M
FY17-−$33.3M
FY16$18.5K−$31.8M
FY15$20.1M−$12.8M
FY14$15M−$11.1M
FY13$4M−$10.6M
FY12$15.3M$3.7M
FY11--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400000%−300000%−200000%−100000%0%100000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−1407.5%1.4%
FY24--
FY23−392752.9%369%
FY22−63204.4%−62251.7%
FY21−5470.7%−5469%
FY20−506.8%−502.1%
FY19--
FY18--
FY17--
FY16−172505.3%−171945.1%
FY15−63.7%−63.6%
FY14−74.1%−74%
FY13−265.7%−265.6%
FY1223.8%24%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$72.5M
FY24−$31.1M
FY23−$34.9M
FY22−$46.5M
FY21−$57.5M
FY20−$39.3M
FY19−$52.1M
FY18−$43.5M
FY17−$30.1M
FY16−$30.4M
FY15−$8.5M
FY14−$4.5M
FY13−$15.6M
FY12−$10.8M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Crescent Biopharma
  • Healthcare median
−200000%−150000%−100000%−50000%0%50000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCrescent BiopharmaHealthcare median
FY251.4%−30.6%
FY24-−47%
FY23369%−58%
FY22−62251.7%−80.4%
FY21−5469%−71.8%
FY20−502.1%−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16−171945.1%−36%
FY15−63.6%−37.8%
FY14−74%−35.5%
FY13−265.6%−37.1%
FY1224%−29.1%
FY11-−27.9%